Aardvark Therapeutics Faces Securities Fraud Class Action Lawsuit

The complaint filed against the company alleges that leadership issued materially misleading statements regarding the safety and commercial viability of its drug candidate, ARD-101. Plaintiffs claim the company failed to disclose that the treatment was less safe than represented to the public, leading to an overstatement of its regulatory and clinical prospects. Because of these omissions, shareholders allege they were misled about the true value and risk profile of their investments during the specified period.

The law firm Glancy Prongay Wolke & Rotter LLP is spearheading the litigation, offering representation to those seeking to recover investment losses. While no class has been certified, those who purchased securities during the class period retain the right to participate or remain absent class members. Interested parties must file their motions with the court by the October 13 deadline, after which the legal process will determine the trajectory of the claims.